A Novel Nomogram to Predict the Postoperative Overall Survival in Gastrointestinal Cancer Patients

NCT05620537 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 808

Last updated 2023-02-13

No results posted yet for this study

Summary

This multicenter retrospectively observational cohort study was conducted on participants with histologically confirmed gastric and colorectal cancer who underwent radical surgery in 11 medical centers in China from August 1, 2015, to June 31, 2018. Baseline clinicopathologic data and nutritional status assessments including Nutrition Risk Screening 2002 (NRS 2002) score and Patient-generated Subjective Global Assessment (PG-SGA) rating were collected. Variables will be screened using the least absolute shrinkage and selection operator (LASSO) regression model and Cox regression analysis. Internal and external validations will be performed via the receiver operating curve (ROC), the area under the curve (AUC), the concordance index (C-index), calibration plots, decision curve analysis (DCA), and Five folds cross-validation by 200 times.

Conditions

  • Gastrointestinal Cancers - Stomach
  • Gastrointestinal Cancers - Colorectal
  • Prognosis
  • Survival Analysis
  • Nutrition Assessment

Interventions

OTHER

observation

There are no interventions.

Sponsors & Collaborators

  • Jiangsu Cancer Institute & Hospital

    collaborator OTHER
  • Xijing Hospital

    collaborator OTHER
  • Northern Jiangsu People's Hospital

    collaborator OTHER
  • The Affiliated Hospital of Qingdao University

    collaborator OTHER
  • Shanghai 10th People's Hospital

    collaborator OTHER
  • West China Hospital

    collaborator OTHER
  • First Affiliated Hospital of Kunming Medical University

    collaborator OTHER
  • The Second Affiliated Hospital of Harbin Medical University

    collaborator OTHER
  • Peking Union Medical College Hospital

    collaborator OTHER
  • Chinese PLA General Hospital

    collaborator OTHER
  • Wang Xinying

    lead OTHER

Principal Investigators

  • Xinying Wang, M.D. · Jinling Hospital, China

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-10
Primary Completion
2022-11-25
Completion
2022-11-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05620537 on ClinicalTrials.gov